First, we treated prostate cancer cells for four hours with increasing doses of the highly specific inhibitor against each kinase, to establish doses that robustly decrease RNA Pol II phosphorylation: 500 nM for CDK7 and CDK12/13 inhibitors and 20 nM for CDK9 inhibitor were found to achieve this (Fig. 1B). This evidence concerns the gene CDK9 and prostate carcinoma.